Treatment of Cutaneous Melanoma

Mary Ann N Johnson, April W. Armstrong

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.

Original languageEnglish (US)
Title of host publicationEvidence-Based Dermatology: Third Edition
PublisherWiley Blackwell
Pages231-240
Number of pages10
ISBN (Print)9781118357606, 9781118357675
DOIs
StatePublished - Aug 11 2014
Externally publishedYes

Fingerprint

Melanoma
Skin
Hutchinson's Melanotic Freckle
Therapeutics
Sentinel Lymph Node Biopsy
Survival
Cytotoxins
B-Cell Lymphoma
Incidence

Keywords

  • Antisense therapy
  • Cytotoxic chemotherapeutic agents
  • Lentigo maligna melanoma (LMM)
  • Metastatic malignant melanoma
  • Primary cutaneous melanoma
  • Sentinel lymph-node biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Johnson, M. A. N., & Armstrong, A. W. (2014). Treatment of Cutaneous Melanoma. In Evidence-Based Dermatology: Third Edition (pp. 231-240). Wiley Blackwell. https://doi.org/10.1002/9781118357606.ch31

Treatment of Cutaneous Melanoma. / Johnson, Mary Ann N; Armstrong, April W.

Evidence-Based Dermatology: Third Edition. Wiley Blackwell, 2014. p. 231-240.

Research output: Chapter in Book/Report/Conference proceedingChapter

Johnson, MAN & Armstrong, AW 2014, Treatment of Cutaneous Melanoma. in Evidence-Based Dermatology: Third Edition. Wiley Blackwell, pp. 231-240. https://doi.org/10.1002/9781118357606.ch31
Johnson MAN, Armstrong AW. Treatment of Cutaneous Melanoma. In Evidence-Based Dermatology: Third Edition. Wiley Blackwell. 2014. p. 231-240 https://doi.org/10.1002/9781118357606.ch31
Johnson, Mary Ann N ; Armstrong, April W. / Treatment of Cutaneous Melanoma. Evidence-Based Dermatology: Third Edition. Wiley Blackwell, 2014. pp. 231-240
@inbook{97d230ba15304c5fa11a3e2d46f7d104,
title = "Treatment of Cutaneous Melanoma",
abstract = "This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.",
keywords = "Antisense therapy, Cytotoxic chemotherapeutic agents, Lentigo maligna melanoma (LMM), Metastatic malignant melanoma, Primary cutaneous melanoma, Sentinel lymph-node biopsy",
author = "Johnson, {Mary Ann N} and Armstrong, {April W.}",
year = "2014",
month = "8",
day = "11",
doi = "10.1002/9781118357606.ch31",
language = "English (US)",
isbn = "9781118357606",
pages = "231--240",
booktitle = "Evidence-Based Dermatology: Third Edition",
publisher = "Wiley Blackwell",

}

TY - CHAP

T1 - Treatment of Cutaneous Melanoma

AU - Johnson, Mary Ann N

AU - Armstrong, April W.

PY - 2014/8/11

Y1 - 2014/8/11

N2 - This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.

AB - This chapter briefly discusses the primary cutaneous melanoma and its incidence, risk factors, diagnosis, prognosis and treatment objectives. It also describes the recommendations for surgical excision margins based on the Breslow thickness of the melanoma. The management of patients with lentigo maligna (LM) or lentigo maligna melanoma (LMM), and the role of sentinel lymph-node biopsy are discussed in detail. The chapter also discusses the therapies to improve overall survival in patients with metastatic malignant melanoma. It also discusses the question: Does antisense therapy against B-cell lymphoma 2 improve outcomes in patients with metastatic melanoma. Developments in the systemic treatment of melanoma have resulted in improved survival for advance metastatic melanoma (Stage IV). The role of cytotoxic chemotherapeutic agents, as monotherapy and in combination regimens, is limited in initial treatment for metastatic melanoma.

KW - Antisense therapy

KW - Cytotoxic chemotherapeutic agents

KW - Lentigo maligna melanoma (LMM)

KW - Metastatic malignant melanoma

KW - Primary cutaneous melanoma

KW - Sentinel lymph-node biopsy

UR - http://www.scopus.com/inward/record.url?scp=84926400451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926400451&partnerID=8YFLogxK

U2 - 10.1002/9781118357606.ch31

DO - 10.1002/9781118357606.ch31

M3 - Chapter

AN - SCOPUS:84926400451

SN - 9781118357606

SN - 9781118357675

SP - 231

EP - 240

BT - Evidence-Based Dermatology: Third Edition

PB - Wiley Blackwell

ER -